Jazz Pharmaceuticals to Acquire Chimerix for $935 Million

Jazz Pharmaceuticals has announced a definitive agreement to acquire Chimerix for a total cash consideration of approximately $935 million. The acquisition, expected to close in the second quarter of 2025, will enable Jazz to expand its oncology portfolio with the addition of Chimerix's leading clinical asset, dordaviprone. Dordaviprone is a promising treatment for H3 K27M-mutant diffuse glioma, a rare brain tumor predominantly affecting children and young adults, with no currently FDA-approved therapies. As part of the agreement, Jazz will pay $8.55 per share for Chimerix, reflecting a 72% premium on the closing price as of March 4, 2025. The acquisition is expected to enhance Jazz's presence in the rare oncology space and create new revenue streams, with dordaviprone potentially becoming a standard of care if approved by the FDA. Both companies have expressed optimism about leveraging their combined R&D and commercial capabilities to maximize the therapy's impact.